GLP-1 Agonist Safety Overview

Overview

GLP-1 receptor agonists (including semaglutide, tirzepatide, and liraglutide) are a class of medications used for type 2 diabetes and weight management. This page summarizes their collective safety profile based on clinical trial data and post-marketing surveillance.

Note: Tirzepatide is technically a dual GIP/GLP-1 agonist but shares many safety characteristics with GLP-1-only medications.

---

Common Side Effects

The most frequently reported side effects are gastrointestinal in nature. These typically occur during dose initiation and titration, and often diminish over time.

Gastrointestinal Effects

Side Effect	Incidence Range	Notes
Nausea	10-20%	Most common; usually transient
Diarrhea	8-17%	Dose-dependent
Vomiting	5-11%	More common during dose escalation
Constipation	5-10%	Less common than other GI effects
Abdominal pain	5-8%	Usually mild
Dyspepsia	4-8%	Indigestion, heartburn
Decreased appetite	5-10%	Often considered therapeutic effect

Managing GI Side Effects

Clinical trials and clinical practice suggest these strategies may help:

• Gradual dose titration (following recommended schedules)
• Eating smaller meals
• Avoiding high-fat or greasy foods
• Staying hydrated
• Timing injections consistently

Most patients find GI symptoms improve within 4-8 weeks of each dose increase.

---

Serious Adverse Events

While less common, certain serious adverse events have been associated with GLP-1 agonists.

Pancreatitis

Finding	Details
Incidence	Rare (estimated at less than 1%)
Clinical trial data	Slightly elevated risk vs placebo in some studies
FDA warning	Listed in prescribing information

Symptoms to report immediately:

• Severe abdominal pain (may radiate to back)
• Nausea and vomiting that doesn’t improve
• Abdominal tenderness

Recommendation: Discontinue if pancreatitis is suspected; do not restart.

Gallbladder Disease

Finding	Details
Incidence	1-3% in weight loss trials
Risk factor	Rapid weight loss increases risk
Types	Cholelithiasis (gallstones), cholecystitis

Patients experiencing significant weight loss should be monitored for gallbladder symptoms.

Acute Kidney Injury

Finding	Details
Mechanism	Often related to dehydration from GI effects
Risk factors	Pre-existing kidney disease, dehydration
Prevention	Adequate hydration, monitoring during illness

Patients with nausea, vomiting, or diarrhea should maintain adequate fluid intake.

Diabetic Retinopathy Complications

Finding	Details
Observed in	Some trials of GLP-1 agonists
Proposed mechanism	Rapid improvement in glycemic control
At-risk patients	Those with pre-existing retinopathy

Patients with diabetic retinopathy should have regular eye examinations.

---

Boxed Warnings

All GLP-1 receptor agonists (and tirzepatide) carry a boxed warning for thyroid C-cell tumors.

Thyroid C-Cell Tumors

Important context:

• This finding was observed in rats and mice given high doses
• Human thyroid C-cells have far fewer GLP-1 receptors than rodent C-cells
• No increase in MTC has been definitively confirmed in humans to date
• Post-marketing surveillance is ongoing

Who should NOT use these medications:

• Patients with personal history of MTC
• Patients with family history of MTC
• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

---

Contraindications

Absolute Contraindications

Contraindication	Applies To	Reason
Personal history of MTC	All GLP-1 agonists	Boxed warning
Family history of MTC	All GLP-1 agonists	Boxed warning
MEN 2 syndrome	All GLP-1 agonists	Boxed warning
Known hypersensitivity	Specific product	Allergic reaction risk
Type 1 diabetes	All products	Not indicated; risk of DKA

Relative Precautions

Condition	Consideration
History of pancreatitis	Use with caution; monitor
Severe GI disease	May worsen symptoms
Diabetic retinopathy	Monitor closely
Chronic kidney disease	Hydration monitoring; dose may not need adjustment
Pregnancy	Not recommended; discontinue 2 months before conception
Breastfeeding	Limited data; discuss with provider

---

Drug Interactions

Oral Medications

GLP-1 agonists delay gastric emptying, which may affect absorption of oral medications.

Interaction Type	Examples	Management
Absorption affected	Some oral medications	Monitor effectiveness
Insulin/sulfonylureas	Hypoglycemia risk	May need dose reduction
Oral contraceptives	Potentially reduced absorption	Consider backup methods during initiation

Medications That May Increase Hypoglycemia Risk

When combined with insulin or sulfonylureas, GLP-1 agonists may increase hypoglycemia risk. Dose reductions of the other medications may be needed.

---

Clinical Trial Safety Data

Combined Analysis

Based on pooled clinical trial data for GLP-1 agonists:

Safety Measure	Finding
Treatment discontinuation due to AEs	4-7% (vs 1-3% placebo)
Serious adverse events	Generally similar to comparators
Deaths	No increased mortality signal
Cardiovascular safety	Demonstrated in CVOTs (semaglutide SELECT trial)

Long-Term Data

• Most trials lasted 52-72 weeks
• Extension studies show maintained safety profile
• Post-marketing surveillance ongoing
• Cardiovascular outcomes trials have shown benefit or neutrality

---

Post-Marketing Surveillance

Ongoing Monitoring

Since FDA approval, these events are being monitored:

Signal	Status	Notes
Thyroid cancer	Ongoing monitoring	No confirmed signal to date
Pancreatitis	Known risk	Consistent with trial data
Gallbladder events	Known risk	Consistent with trial data
Ileus/bowel obstruction	Under review	Rare reports
Aspiration during anesthesia	Under review	Due to delayed gastric emptying

Anesthesia Considerations

In 2023, the American Society of Anesthesiologists issued guidance regarding GLP-1 agonists and elective procedures:

• Consider holding GLP-1 agonists before procedures requiring anesthesia
• Discuss with your anesthesiologist and prescribing physician
• Increased aspiration risk due to delayed gastric emptying

---

Reporting Adverse Events

How to Report

If you experience a serious adverse event:

1. Contact your healthcare provider immediately
2. Report to FDA MedWatch:
   • Online: www.fda.gov/medwatch
   • Phone: 1-800-FDA-1088
   • Mail: FDA MedWatch form

What to Report

• Serious adverse events
• Unexpected side effects
• Quality problems with medication
• Therapeutic failures

---

Summary

GLP-1 receptor agonists have a well-characterized safety profile based on extensive clinical trial data and growing post-marketing experience.

Key points:

• Most common side effects are gastrointestinal and often improve over time
• Serious events (pancreatitis, gallbladder disease) are rare but require monitoring
• Boxed warning for thyroid C-cell tumors based on animal studies
• Contraindicated in patients with MTC history, family history of MTC, or MEN 2
• Drug interactions possible, especially with insulin and oral medications

---

Sources

Source	Type	Year
FDA Mounjaro Prescribing Information	Regulatory	2022
FDA Ozempic Prescribing Information	Regulatory	2017
FDA Zepbound Prescribing Information	Regulatory	2023
ASA Practice Advisory on GLP-1 Agonists	Guideline	2023
SURPASS Clinical Trial Program	Clinical trials	2021-2023
SURMOUNT Clinical Trial Program	Clinical trials	2022-2023

---

This safety information is for educational purposes only. Always consult your healthcare provider and refer to official prescribing information for complete safety data.